Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors

NCT02004717 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: DS-8895a

Sponsor

Daiichi Sankyo Co., Ltd.